

Supplementary Table S3. Sensitivity analyses of OS and RFS using different cutoff values

		PSMA/CD34 ratio cutoff: 30%				PSMA/CD34 ratio cutoff: 40%				PSMA/CD34 ratio cutoff: 60%			
		OS		RFS		OS		RFS		OS		RFS	
		p-value	HR ^a (95% CI)	p-value	HR ^a (95% CI)	p-value	HR ^a (95% CI)	p-value	HR ^a (95% CI)	p-value	HR ^a (95% CI)	p-value	HR ^a (95% CI)
Primary CRC PSMA (concurrent metastasis) (n = 41)													
PSM	0.	2.36	0.	3.465	0.0	2.324	0.17	3.465	0.08	2.154	0.16	5.48	
A high vs. low ^a	03	(1.086	1	(0.572	33	(1.069–5.054)	6	(0.572	8	(0.891–5.204)	5	(0.496–60.52)	
	0	–5.129	7	–									
			6	20.99)				20.99)					
Hepatic metastasis PSMA (concurrent metastasis) (n = 41)													
PSM	0.	0.773	0.	0.348	0.2	0.546	0.33	0.348	0.26	0.546	0.33	0.348	
A high vs. low ^a	57	(0.312	3	(0.041	64	(0.189–1.578)	4	(0.041	4	(0.189–1.578)	4	(0.041–2.961)	
	7	–	3	–				–					
		1.913)	4	2.961)				2.961)					
Hepatic metastasis PSMA (concurrent metastasis and untreated) (n = 34)													
PSM	0.	0.565	0.	0.429	0.1	0.441	0.45	0.429	0.18	0.441	0.45	0.429	
A high vs. low ^a	30	(0.191	4	(0.046	88	(0.131–1.490)	8	(0.046	8	(0.131–1.490)	8	(0.046–4.003)	
	1	–	5	–				–					
		1.667)	8	4.003)				4.003)					

OS, overall survival; RFS, recurrence free survival; HR, hazard ratio; CI, confidence interval; PSMA, prostate-specific membrane antigen.

^aThe reference group for all cutoff analyses was PSMA low (PSMA/CD34 ratio <30%, <40%, or <60%, according to the respective cutoff).